AbbVie Price Target Raised to $195.00/Share From $185.00 by B of A Securities
AbbVie Analyst Ratings
BofA Securities Initiates AbbVie(ABBV.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
AbbVie Is Maintained at Outperform by BMO Capital
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
AbbVie Analyst Ratings
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $205
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $218
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $215
UBS Downgrades AbbVie(ABBV.US) to Hold Rating, Raises Target Price to $195
TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $225
AbbVie Is Maintained at Buy by TD Cowen
AbbVie Analyst Ratings
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $212
AbbVie (ABBV) Gets a Buy From Barclays
Barclays Adjusts Price Target on AbbVie to $212 From $200, Maintains Overweight Rating